Myosin Therapeutics Closes $3M Second Seed Funding
Summary
Myosin Therapeutics, a Jupiter, FL-based biotechnology company developing novel therapies for cancer and neurological disorders, closed its second Seed funding round, raising over $3M to supplement investment from the National Institutes of Health. The Seed was led by DeepWork Capital, Florida Opportunity Fund, and Mint12 Pharma, along with Dynagrow Capital, the private investment management affiliate of Fred Hassan, Mayo Clinic Ventures, and The Sontag Innovation Fund. Led by CEO Dr. Courtney Miller, Myosin Therapeutics is a biotechnology company spun out of The Herbert Wertheim UF Scripps Institute (formerly Scripps Research, Florida), which is focused on developing therapies for neuroscience and oncology indications using a platform that targets molecular nanomotor proteins. Myosin Therapeutics is advancing its lead compound, MT-125, to treat glioblastoma, the most aggressive brain cancer with an average survival time of only 8 months. The FDA granted orphan drug designation to MT-125 for malignant gliomas, underscoring its potential to improve outcomes for patients with this devastating disease.